Rhythm Pharmaceuticals Inc (RYTM) Director David P. Meeker Buys 25,000 Shares

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director David P. Meeker acquired 25,000 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, October 10th. The shares were purchased at an average cost of $17.00 per share, with a total value of $425,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Rhythm Pharmaceuticals Inc (NASDAQ RYTM) opened at 26.01 on Wednesday. Rhythm Pharmaceuticals Inc has a one year low of $23.99 and a one year high of $26.50. The company’s market capitalization is $678.18 million. The firm’s 50-day moving average price is $25.29 and its 200 day moving average price is $25.29.

ILLEGAL ACTIVITY WARNING: “Rhythm Pharmaceuticals Inc (RYTM) Director David P. Meeker Buys 25,000 Shares” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://ledgergazette.com/2017/10/11/rhythm-pharmaceuticals-inc-rytm-director-david-p-meeker-buys-25000-shares.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply